Abstract:Sarcoidosis is a systemic granulomatous disease that is triggered by an autoimmune process, and is now a well recognized but uncommon complication of antiviral therapy for Hepatitis C virus (HCV) infection, likely related to its immunomodulatory effects. The clinical presentation of HCV related sarcoidosis is as varied as systemic sarcoidosis, but ocular presentation alone has not been reported previously. We present a 23 year-old female who developed visual disturbances due to ocular sarcoidosis during the co… Show more
“…However, uveitis has also been reported to be due to interferon-induced sarcoidosis (21). Visual changes have been reported with interferon and are most commonly associated with retinopathy, ischemic optic nerve injury (22) or retinal vein thrombosis (23).…”
Objectives
Interferon treatment for chronic viral hepatitis C (HCV) has been associated with the development of retinopathy in 19–29% of adults. Our purpose is to describe the ophthalmological complications of pegylated interferon (PEG) α2a with either placebo or ribavirin in children with chronic HCV (THE PEDS-C TRIAL).
Methods
Prospective comprehensive ophthalmologic examinations including slit lamp at enrollment and after 24 and 48 weeks of treatment of 114 children participating in a randomized clinical trial.
Results
128 children were screened for entry of which 123 had an eye exam and no child had existing retinal disease. 114 children were eligible and were treated. 110 children had an eye exam at 24 weeks and 103 at 48 weeks. 3 of 114 subjects (2.6%) developed documented (n=2) or possible (1) serious eye complications: One developed evidence of ischemic retinopathy (cotton wool spots) by week 24, one developed uveitis by week 48, and one reported at week 48 transient (<4 hours) monocular blindness that had occurred at week 36 with a subsequent normal exam at week 48.
Conclusions
Ophthalmologic complications are infrequent in children who are treated with PEG α2a for HCV (2–3%). Because of the potential severity of ischemic retinopathy and uveitis, prospective ocular assessment should remain part of the monitoring strategy for children who are treated with interferon for HCV.
“…However, uveitis has also been reported to be due to interferon-induced sarcoidosis (21). Visual changes have been reported with interferon and are most commonly associated with retinopathy, ischemic optic nerve injury (22) or retinal vein thrombosis (23).…”
Objectives
Interferon treatment for chronic viral hepatitis C (HCV) has been associated with the development of retinopathy in 19–29% of adults. Our purpose is to describe the ophthalmological complications of pegylated interferon (PEG) α2a with either placebo or ribavirin in children with chronic HCV (THE PEDS-C TRIAL).
Methods
Prospective comprehensive ophthalmologic examinations including slit lamp at enrollment and after 24 and 48 weeks of treatment of 114 children participating in a randomized clinical trial.
Results
128 children were screened for entry of which 123 had an eye exam and no child had existing retinal disease. 114 children were eligible and were treated. 110 children had an eye exam at 24 weeks and 103 at 48 weeks. 3 of 114 subjects (2.6%) developed documented (n=2) or possible (1) serious eye complications: One developed evidence of ischemic retinopathy (cotton wool spots) by week 24, one developed uveitis by week 48, and one reported at week 48 transient (<4 hours) monocular blindness that had occurred at week 36 with a subsequent normal exam at week 48.
Conclusions
Ophthalmologic complications are infrequent in children who are treated with PEG α2a for HCV (2–3%). Because of the potential severity of ischemic retinopathy and uveitis, prospective ocular assessment should remain part of the monitoring strategy for children who are treated with interferon for HCV.
“…Despite many reports of systemic sarcoid following interferon use for hepatitis C, cases of induced ophthalmic and orbital sarcoid remain rare. Five cases of presumed sarcoid uveitis following interferon use have been reported, although only 1 involved an ophthalmic presentation without prior systemic sarcoid (Yan et al, 2008). Sarcoid-like granulomatous dacryoadenitis, without any other features of sarcoidosis, has also recently been reported in a patient receiving interferon alpha and ribavarin (Hwang and Gausas, 2008).…”
Sarcoidosis is an increasingly well-recognised complication of interferon therapy for hepatitis C infection, primarily manifesting with cutaneous or pulmonary involvement. However, we present an unusual case of sarcoid-related dacryoadenitis in a 67-year-old Caucasian lady following such treatment. The literature relating to ophthalmic presentations of interferon-related sarcoidosis is reviewed, and the potential for confusion with interferon-induced thyroid- associated orbitopathy is discussed.
“…Also, Hirano et al published a case of uveitis in a patient with hilar and mediastinal lymph nodes enlargement by histologically proven sarcoidosis which developed 2 years after IFN-alpha treatment for chronic hepatitis C virus infection [19]. Recently, a case of sarcoidosis, presenting as granulomatous uveitis under therapy with pegylated IFN and ribavirin, was reported by Yan et al [44].…”
Section: Discussionmentioning
confidence: 99%
“…The most frequent are flu-like symptoms, autoimmune and autoinflammatory disorders, depression, and chronic fatigue syndrome [3,11,12,14,21,33,38,44]. The most common ocular side-effect of IFN-therapy is IFN-induced retinopathy [16,17].…”
Uveitis can be a sign of sarcoidosis induced by interferon alpha. Further studies are required to support the observation that with early diagnosis the prognosis of uveitis seems to be good.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.